Pexidartinib CAS# 1029044-16-3 吡昔替尼
Pexidartinib, also know as PLX-3397, is a CSF1R inhibitor with IC50 of 20 nM in development by Plexxikon for the treatment of tenosynovial giant cell tumors. It is in a phase 3 clinical trial for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS).
📌 参考资料/链接：
Reference: Chen, Dongsheng; Zhang, Yi; Li, Jianqi; Liu, Yu. Exploratory Process Development of Pexidartinib through the Tandem Tsuji-Trost Reaction and Heck Coupling. Synthesis. Volume 51. Issue 12. Pages 2564-2571. Journal; Online Computer File. (2019).
Reference: Chen, Dongsheng; Zhang, Yi; Li, Jianqi; Liu, Yu. Exploratory Process Development of Pexidartinib through the Tandem Tsuji-Trost Reaction and Heck Coupling. Synthesis. Volume 51. Issue 12. Pages 2564-2571. Journal; Online Computer File. (2019).
📄 详细内容
CAS No. 1029044-16-3 吡昔替尼Pexidartinib synthetic routes
Chen, Dongsheng; Zhang, Yi; Li, Jianqi; Liu, Yu. Exploratory Process Development of Pexidartinib through the Tandem Tsuji-Trost Reaction and Heck Coupling. Synthesis. Volume 51. Issue 12. Pages 2564-2571. Journal; Online Computer File. (2019).
产品链接: CAS No. 1029044-16-3 ››
Chen, Dongsheng; Zhang, Yi; Li, Jianqi; Liu, Yu. Exploratory Process Development of Pexidartinib through the Tandem Tsuji-Trost Reaction and Heck Coupling. Synthesis. Volume 51. Issue 12. Pages 2564-2571. Journal; Online Computer File. (2019).
产品链接: CAS No. 1029044-16-3 ››